OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2025
(2)
2020
(2)
2017
(2)
2018
(1)
2013
(1)
2011
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.
Not available
S-EPMC3577773
|
biostudies-literature
Cite
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.
Not available
S-EPMC3167813
|
biostudies-literature
Cite
Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders.
Not available
S-EPMC5740257
|
biostudies-literature
Cite
Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial.
Not available
S-EPMC6276348
|
biostudies-literature
Cite
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area.
Not available
S-EPMC7273245
|
biostudies-literature
Cite
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
Not available
S-EPMC7499171
|
biostudies-literature
Cite
GRIN2B
encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects.
Not available
S-EPMC5656050
|
biostudies-literature
Cite
Global anaesthesia practice using inguinal hernia surgery as a tracer condition: a secondary analysis of an international prospective cohort study.
Not available
S-EPMC12519944
|
biostudies-literature
Cite
Global hospital-based disease management of acute diverticulitis: a prospective, international cohort study.
Not available
S-EPMC12512976
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets